- Company
- Biktarvy, applies to the expansion of pediatric indications
- by Eo, Yun-Ho Jan 18, 2023 06:04am
- HIV treatment Biktarvy is aiming to expand pediatric indications in Korea. According to related industries, Gilead Science Korea recently submitted an application to expand indications for pediatric patients who weigh at least 14kg to 25kg of the HIV compound Biktarvy and have no experience in antiretroviral treatment or have been suppressed
- Company
- Curing terminal cancer without treatment options
- by Jan 17, 2023 06:02am
- Mr. A, a 60-year-old Korean male patient, was diagnosed with gastric cancer several years ago. After struggling to treat the disease for several years, the hospital told A that there was no other treatment option available for him and that he may not be able to live for more than 6 months. As a last resort, A registered to enroll in the KOSM
- Company
- Despite the largest export of diagnostic kits ever, we canno
- by Kim, Jin-Gu Jan 17, 2023 06:02am
- Exports of domestic diagnostic kits broke the record last year. However, export performance in the second half of the year is on the decline. Analysts say that as the global COVID-19 situation calms down, exports of diagnostic kits, which have been on a high march, are returning to the level of previous years. According to the Korea Customs S
- Company
- Stelara biosimilar of Dong-A ST succeeded in clinical trials
- by Chon, Seung-Hyun Jan 17, 2023 06:02am
- Dong-A ST announced on the 16th that the Stelara biosimilar DMB-3115 has confirmed its safety and effectiveness in clinical trials. On the same day, Dong-A ST introduced the results of DMB-3115's global phase 3 clinical trial top line and announced that it would apply for item permission to the U.S. and European health authorities in the first h
- Company
- Novartis charged with 'rebate' has been fined
- by jung, sae-im Jan 16, 2023 07:47pm
- Novartis and Media Fines…Suspension of imprisonment for those involved Novartis Korea, accused of providing illegal rebates of about 2.6 billion won to doctors, was finally fined by the Supreme Court. On the 12th, the Supreme Court rejected the appeal filed by Novartis Korea, related parties, and media outlets who were convicted in the o
- Company
- Next-Generation ADC Enhertu launches in Korea
- by jung, sae-im Jan 16, 2023 07:39pm
- Enhertu, which Korean breast cancer patients urged for quick permission last year, was released in Korea this month. Analysts say that it will change the paradigm of secondary treatment for HER2-positive breast cancer with a superior effect compared to existing treatments. Daiichi Sankyo held a press conference at the Westin Chosun Hotel on the
- Company
- Last year's drug trade deficit was the largest ever
- by Kim, Jin-Gu Jan 16, 2023 06:03am
- Vaccine exports hit an all-time high, but have been on the decline since the second half of the year. Last year, pharmaceutical exports fell 23% year-on-year. The export performance of medicines, which had been on a high march for two years from 2020 to 2021, is gradually returning to the previous year's level as the global spread of COVID-19 su
- Company
- GM Lee Seung-woo to leave Gilead Sciences Korea
- by Eo, Yun-Ho Jan 16, 2023 06:02am
- Paul Seung-woo Lee (65), who has served as the General Manager of Gilead Sciences Korea and led the company since its establishment, will be leaving the company. According to industry sources, Lee has recently expressed his intent to resign upon the expiry of his term to the company. Accordingly, Gilead is currently in the process of hiri
- Company
- Bosulif approved in Korea 11 years after US approval
- by Jan 16, 2023 06:02am
- The Ministry of Food and Drug Safety approved the new drug for chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), ‘Bosulif (bosutinib)’ in Korea. The drug was first approved in the US in 2012. With the approval, the treatment options for Ph+CML increased to 6, excluding the first-generation drug. Accor
- Company
- RET-targeted Retevmo lands in general hospitals in KOR
- by Eo, Yun-Ho Jan 13, 2023 06:02am
- The RET-targeted anticancer therapy ‘Retevmo’ may now be prescribed at general hospitals in Korea. According to industry sources, Lilly Korea’s, Lilly Korea’s Retevmo (selpercatinib) passed the drug committees of tertiary hospitals in Korea including the Samsung Medical Center, Seoul National University Hospital, and Seoul St. Mary’s H
